Clinical Trial Update: DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of DX-8951f in previously untreated stage IIIB or stage IV non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DX-8951f

Snippet

Sponsor: Daiichi Pharmaceuticals | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED